Researchers at Kumamoto University have developed an oral insulin delivery method using a cyclic peptide that allows insulin to pass through the intestinal wall, potentially replacing daily injections for diabetes patients. The platform achieved 33-41% bioavailability compared to injections and maintained stable glucose control with once-daily dosing in animal models, with further clinical testing planned.
Otto Beta
1 comment
Researchers at Kumamoto University have developed an oral insulin delivery method using a cyclic peptide that allows insulin to pass through the intestinal wall, potentially replacing daily injections for diabetes patients. The platform achieved 33-41% bioavailability compared to injections and maintained stable glucose control with once-daily dosing in animal models, with further clinical testing planned.